Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0618—Cells of the nervous system
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0618—Cells of the nervous system
  • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0618—Cells of the nervous system
  • C12N5/0623—Stem cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0634—Cells from the blood or the immune system
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N33/56966—Animal cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Definitions

• the present invention relates to a homogeneous, pure population of mammalian astrocyte restricted precursor cells which are CD44 immunoreactive and generate astrocytes but not oligodendrocytes.
• the present invention is also related to methods for isolating a homogeneous, pure population of these mammalian astrocyte restricted precursor cells.
• the present invention relates to use of mammalian astrocyte restricted precursor cells in the development of new transplantation techniques and to enhance myelination and/or reduce necrosis and glial scar formation upon administration to animals.
• the astrocyte restricted precursor cells and pharmaceutical compositions comprising the same may thus be used to treat disorders of the nervous system resulting from trauma or disease which have in some way damaged the nerve tissue. These cells are also useful in identifying mammalian genes specific to selected stages of development.
• Multipotent cells which are nestin immunoreactive and capable of differentiating into astrocytes, neurons, and oligodendrocytes have been identified by multiple investigators at various stages of development. In addition to multipotent precursors, other more restricted precursors have also been identified. Different populations of cells can be distinguished by differences in culture conditions, self-renewal capability, as well as in their ability to integrate and to differentiate following transplantation.
• Multipotent human neural stem cells have been isolated from fetal and adult tissue (Chalmers-Redman et al. Neuroscience 1997 76:1121-1128; Svendsen et al. J. Neuroscience Methods 1998 85:141-152; Vescovi et al. Exp. Neurology 1999 156:71-83; Carpenter et al. Exp. Neurology 1999 158:265-278; Quinn et al. J. Neuroscience Res. 1999 57:590-602; Piper et al. J. Neurophysiology 2000 84:534-548). These cells give rise to glia and neurons, can be grown under different culture conditions, and show different growth factor requirements.
• Human neuron restricted precursors have also been described (Piper et al. J. Neurophysiol. 2000 84:534-548). Piper et al. used E-NCAM immunoreactivity to isolate neuronal precursor cells while Goldman and colleagues used neuron specific promoters to isolate neuronal precursors (Roy et al. Nat. Med. 2000 6(3):271-7; Roy et al. J. Neurosci. Res. 2000 59(3):321-31; Wang et al. Dev. Neurosci. 2000 22(1-2):167-76). Human neuronal restricted precursor cells have been isolated from the adult ventricular zone and hippocampus as well as from fetal tissue at multiple stages of development. These cells differ from human neuroepithelial cells by their expression of early neuronal markers such as NCAM, alpha-1 tubulin and beta-III tubulin.
• Proliferative adult human oligodendrocyte precursors have been isolated from adult human white matter (Prabhakar et al. Brain Res. 1995 672(1-2):159-69, Raine et al. Lab. Invest. 1981 45(6):534-46; Scolding et al. Neuroreport 1995 6(3):441-5; Scolding et al. Neuroscience 1999 89(1):1-4) using cell surface markers. Others have used promoter-reporter constructs to isolate oligodendrocytes and their precursors from fetal and adult tissue. A2B5 immunoreactivity has been utilized to isolate glial precursors that are capable of differentiating into astrocytes and oligodendrocytes (U.S. Pat. No. 6,235,527).
• Quinn and colleagues describe a mixed population of multipotent stem cells that can become altered in their properties after prolonged culture. These cells have been suggested to be astrocyte restricted precursor cells. However, oligodendrocyte differentiation has not been tested. Further, no information on antigenic expression, cytokine dependence, response to growth factors, expression of GFAP/S100 ⁇ , or A2B5 is available. The cells of Quinn et al. were obtained by sequentially passaging multipotent stem cells from cultured human spinal cord tissue.
• a putative astrocyte precursor cell has also been described by Barres et al. (J. Neurosci. 1999 19(3):1049-61). This cell was isolated from the optic nerve and its existence in any other part of the brain is unknown. This cell is A2B5 immunoreactive and thus resembles the oligodendrocyte precursor O2A. The cells can be distinguished from the O2A cells mainly by their failure to develop into oligodendrocytes under conditions in which the O2A cells readily generate oligodendrocytes. This cell is Pax-6-positive and dies when exposed to serum. Immunoreactivity with CD44 is unknown.
• the present invention is directed to astrocyte restricted precursor cells, pharmaceutical compositions comprising the same, and methods of utilizing the astrocyte restricted precursor cells to treat mammals with damage to the nervous systems.
• the astrocyte restricted precursor cells of the present invention are not immortalized. These cells do not express A2B5. Further, these cells differ from stem and progenitor cell populations in their expression of CD44 and their ability to differentiate into astrocytes under conditions in which other populations differentiate into neurons or oligodendrocytes.
• one aspect of the present invention relates to an isolated, pure homogeneous population of mammalian astrocyte restricted precursor cells which is CD44 immunoreactive and can generate astrocytes but not oligodendrocytes.
• Another aspect of the present invention relates to a method for isolating a pure homogeneous population of mammalian astrocyte restricted precursor cells.
• the pure homogeneous population of astrocyte restricted precursor cells is isolated from a heterogeneous or mixed population of mammalian cells via CD44 immunoreactivity.
• Another aspect of the present invention relates to methods for development of new transplantation techniques using these mammalian astrocyte restricted precursor cells.
• compositions comprising the mammalian astrocyte restricted precursor cells and methods of using these compositions to treat patients with damage of the nervous system.
• the compositions and methods are used to enhance myelination of mammalian neuronal cells.
• the compositions and methods are used to reduce glial scar formation and necrosis.
• Another aspect of the present invention relates to methods for identifying mammalian genes specific to selected stages of development using these astrocyte restricted precursor cells.
• differentiated cells For cell replacement in the nervous system, differentiated cells are ultimately required. However, extensive studies have shown that differentiated cells do not survive well following transplantation. Therefore, some researchers have focused their efforts on use of precursor cells which have been shown to survive and integrate into the intact or damaged brain.
• the present invention relates to a pure, homogeneous population of mammalian astrocyte restricted precursor cells which can be isolated from various sources of mammalian neural tissue and/or cells including, but not limited to, mammalian embryonic or fetal tissue, mammalian embryonic stem (ES) cell cultures, and glial restricted precursor cells.
• the present invention also relates to methods for isolating a pure, homogeneous population of astrocyte restricted precursor cells from such tissues and cells.
• pure it is meant a population of cells in which greater than 95%, more preferably 99%, exhibit the same characteristics.
• the mammalian tissue or cells from which the astrocyte restricted precursor cells are isolated is either rodent or human.
• the methods for isolation taught herein are also routinely adaptable to cells or tissues from other mammals including, but not limited to, non-human primates, equines, canines, felines, bovines, porcines, ovines, lagomorphs, and the like
• the astrocyte restricted precursor cells of the present invention express CD44. Prior to differentiations these cells also express nestin. Unlike the putative astrocyte restricted cells of Barres et al. (J. Neurosci 1999 19(3):1049-61), the astrocyte restricted precursor cells of the present invention do not express A2B5. Nor do the cells of the present invention express PSANCAM. The cells of the present invention grow well in FGF and EGF. The CD44-positive cells of the present invention do not express GFAP, vimentin or S-100 ⁇ initially, but have the capacity to differentiate into GFAP, vimentin and/or S-100 ⁇ positive cells. Upon differentiation, the cells of the present invention maintain their CD44 immunoreactivity but lose expression of nestin.
• the CD44 positive cells of the present invention can be readily distinguished from glial-restricted precursor cells, multipotent stem cells, neuronal precursors and the putative astrocyte precursor described by Barres et al. (J. Neurosci. 1999 19(3):1049-61) based on antigen expression, cytokine dependence and differentiation ability. See Table 1 which provides a comparison of characteristics of the cells of Barres et al with the astrocyte restricted precursor (ARP) cells of the present invention. TABLE 1 ARP Cells of Characteristic Barres et al. Present Invention A2B5 Expression ++ ⁇ CD44 Expression n.d. ++ Pax-6 Expression ++ ⁇ Clonal analysis n.d. ++ Transplant n.d.
• the astrocyte restricted precursor cells are present in the developing mammalian brain prior to acquisition of GFAP immunoreactivity.
• the CD44+ astrocyte restricted precursor cells can be generated from glial-restricted precursors (GRP) and can be distinguished from GRP cells by antigen expression, cytokine dependency and differentiation ability.
• GRP glial-restricted precursors
• Clonal analysis indicates that a subset of nestin+ cells that are GFAP ⁇ when grown in culture differentiate solely into astrocytes. This subset is quite large and constitutes approximately 11% of the cells analyzed.
• CD44 is specific for this glial population.
• CD44 expression co-localized with astrocytic markers such as GFAP and S-100 ⁇ .
• CD44+ cells were RC1 negative and did not co-express A2B5.
• a small subset of the CD44+ cells were nestin immunoreactive but GFAP negative, thus indicating that these cells represented an astrocyte precursor cell population.
• CD44 positive cells While the number of CD44 positive cells is small, generally in the range of 1-10% of the total number of cells present at any stage of development from E15 to adult, it increases after culture in conditions that promote astrocyte differentiation. CD44 positive cells divide in culture and express low levels of GFAP. Expression of GFAP increases after differentiation while the expression of CD44 is down regulated. CD44 positive cells do not express A2B5 or PLP and, thus, can be distinguished from the bipotential glial-restricted precursor cell. While CD44 expression has been described in other cell types such as macrophages and astrocytes following injury, under the differentiation conditions used herein, CD44 expression was limited to astrocytes and, thus, can be used in accordance with procedures taught herein to identify astrocyte restricted precursor cells.
• CD44 expression can be used to identify and isolate astrocyte restricted precursor cells from various sources of neural tissue including, but not limited to, mammalian ES cell cultures and mammalian fetal or embryonic tissue as well as glial-restricted precursor cells or GRPS methods for isolating glial restricted precursor cells are described in U.S. Pat. No. 6,235,527 the teachings of which are herein incorporated by reference in their entirety.
• This population of astrocyte restricted precursor cells is not immortalized. Further, population of cells does not express A2B5 and differs from stem and progenitor populations in its expression of CD44 and its ability to differentiate into astrocytes under conditions in which other populations differentiate into neurons or oligodendrocytes.
• mammalian neural tubes are dissociated at a stage after astrocyte development, for example week 10 onward in humans or after E16 in rodents, and dissociated cells are triturated to a single cell suspension and labeled with an anti-CD44 antibody. Labeled cells are visualized using a fluorescently labeled secondary antibody targeted to the first antibody and labeled cells are isolated using a selection process.
• selection processes useful in the present invention include, but are not limited to immunopanning, magnetic bead sorting and/or FACS sorting. Detailed magnetic bead and FACS sorting protocols are well known in the art and can be routinely adapted to use of CD44 as the selection marker. Further, as will be understood by those of skill in the art upon reading this disclosure, negative as well as positive selection methods can be used. Thus enrichment of the astrocyte restricted precursor cells of the present invention can be achieved by reselecting from a mixed population cells that express CD44 but do not express A2B5 or E-NCAM and vice versa. Positive and negative selection processes can be used in any sequence and antibodies with a binding profile similar to A2B5 or E-NCAM can be used.
• neural tubes are dissociated at any stage after neural tube closure, for example E8.5 in mouse, E10.5 in rat, and week 5 gestation in human, and cells are maintained in adherent culture for 5 to 40 days. Cells are then removed from culture and CD44 positive cells are isolated via a selection process as described in the preceding paragraph.
• A2B5+ cells are isolated. Cells are then induced to differentiate in culture by growth in astrocyte promoting conditions.
• astrocyte promoting conditions it is meant to include, but is not limited to, addition of bone morphogenetic proteins (BMPs), oncostatin M, serum, Leukemia Inhibitory Factor/Ciliary 35 Neurotrophic Factor (LIF/CTNF) and other members of the cytokine family such as interleukin-6 either singly or in combination for a minimum period of three days.
• BMPs bone morphogenetic proteins
• LIF/CTNF Leukemia Inhibitory Factor/Ciliary 35 Neurotrophic Factor
• these agents are added at concentrations in the range of 1-5 ng/mL.
• CD44+ cells are then isolated via a selection process as described above.
• human fetal tissue derived neural cells have become available through commercial sources such as Cambrex (East Rutherford, N.J.), Clonexpress (Gaithersberg, Md.), ScienCell Research Laboratories (San Diego, Calif.) and Clonetics (San Diego, Calif.). These cells serve as a source of neural tissue and/or cells for isolation of the mammalian astrocyte restricted precursor cells of the present invention in accordance with the methods taught herein.
• Human ES cell lines as a source of the astrocyte restricted precursor cells was also demonstrated in three human cell lines (H1, H7, H9).
• Human ES cells have been previously shown to differentiate into neuronal progenitors that subsequently generate differentiated neurons (Carpenter et al. Exp. Neurol. 2001 172(2):383-97).
• dividing precursor cells that expressed neuronal or glial markers were first identified in ES cells. Differentiation conditions were similar to those described herein and used for generating neurons. Specifically, the first stage of differentiation of the ES cells was induced by the formation of embryonic bodies (EBs) in FBS media with or without 10 ⁇ M all trans-RA.
• EBs embryonic bodies
• EBs were plated onto fibronectin coated plates in defined proliferation media supplemented with 10 ng/mL hEGF, 10 ng/mL hbFGF, 1 ng/mL hPDGF-AA, and 1 ng/mL hIGF-1.
• the EBs adhered to the plates and cells began to migrate and proliferate on the plastic, forming a monolayer. After 3 days in these conditions many cells with neuronal morphology were present. Similar results were found with each human ES cell line.
• dividing cell populations can be identified in cultures of differentiating ES cells based on antibodies that recognize cell surface epitopes. These include A2B5+ cells, PSANCAM+ cells and CD44+ cells. Double labeling experiments following differentiation showed that the CD44+ cells of the ES cells were a unique population of cells that were similar morphologically, antigenically and in their ability to differentiate into astrocytes to the astrocyte restricted cells of the present invention isolated from other sources of neural tissue and cells.
• the astrocyte restricted precursor cells of the present invention have a variety of uses.
• these cells can be used in nonhuman mammalian models to develop new transplantation techniques.
• these cells can be used therapeutically in mammals, more preferably humans, in diseases characterized by neural damage and more particularly astrocyte degeneration.
• administration of the astrocyte restricted precursor cells of the present invention is expected to be useful in enhancing myelination of neurons.
• These cells are also useful in identifying new drugs which enhance survival and proliferation of these cells upon administration.
• the cells can also be used in the reduction of scars. It is well known that fetal astrocytes can incorporate into the brain when transplanted. Fetal cells, as opposed to adult cells, reduce adult glial cell proliferation and scar formation, thereby promoting repair. Astrocyte restricted precursor cells of the present invention can be administered at or near a lesioned site or area of damage one week to several weeks after injury to reduce endogenous adult glial cell proliferation and reduce scar formation.
• the present invention also relates to pharmaceutical compositions comprising these astrocyte restricted precursor cells for use in treatment of mammals with neural damage.
• the cells are provided in injectable form or on implants to promote directed axon regeneration and reduce glial scar formation in the forebrain, and/or in damaged spinal axons of the central nervous system.
• Such compositions are useful in promoting CNS nerve regeneration and/or enhancing myelination and/or reducing glial scar formation.
• Compositions comprising astrocyte restricted precursor cells can be applied, in various different formulations as described infra, to regions or areas of nerve damage.
• compositions can be administered to mammals having nervous system damage resulting from various causes including, but not limited to, trauma, surgery, ischemia, infection, metabolic disease, nutritional deficiency, malignancies and paraneoplastic syndromes, toxic agents, and degenerative disorders of the nervous system.
• Examples of neurodegenerative disorders which can be treated using compositions of the present invention include, but are not limited to, Alzheimer's disease, Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis, progressive supranuclear palsy and peripheral neuropathies.
• Compositions comprising the astrocyte restricted precursor cells of the present invention can also be applied to a wound to reduce scar formation.
• compositions comprising these cells can be applied in accordance with the presence invention to reduce scar formation from a lesion due to, for example, arteriovenous malformation, necrosis, bleeding, and craniotomy, which can secondarily lead to epilepsy.
• the compositions of the present invention can also be used in the treatment of epilepsy by stabilizing the epileptic focus and reducing scar formation.
• compositions of the present invention comprise an effective amount of the isolated astrocyte restricted precursor cells of the present invention and a pharmaceutically acceptable carrier.
• effective amount it is meant a composition comprising approximately 100,000 to about one million cells.
• cell number may vary depending upon the selected site of administration.
• pharmaceutically acceptable carriers include, but are not limited to liquid vehicles such as sterile saline, buffered saline, dextrose and water and semi-liquid or gel-like vehicles which may further comprise a media which impedes, at least in part, the mobility of the cells so as to localize the cells at the site of damage.
• pharmaceutically acceptable carriers may comprise a solid vehicle such as an implant seeded or coated with the cells.
• compositions can be delivered by a wide range of methods to promote CNS nerve regeneration, enhance myelination and/or reduce scar formation.
• Exemplary methods adaptable for use with the compositions of the present invention are set forth in U.S. Pat. No. 5,202,120, the teachings of which are herein incorporated by reference in their entirety.
• the cells are delivered by direct application, for example, by direct injection of the cells in a vehicle into or near the site of nerve damage.
• a vehicle comprising a media which impedes, at least in part, the mobility of the cells so as to localize the cells at the site of damage.
• media which can impede cell mobility include, but are not limited, pastes or gels, such as biodegradable gel-like polymers of fibrin or hydrogels. These semi-solid medias also provide the advantage of impeding migration of scar producing mesenchymal components such as fibroblasts into the site.
• the cells can be delivered via a pharmaceutical compositions comprising a polymer implant or using surgical bypass techniques.
• the astrocyte restricted precursor cells can be seeded or coated onto a polymer implant.
• Various polymer implants with differing composition, geometries and pore size which can be used in this embodiment have been described. Examples include, but are in no way limited to, implants comprising nitrocellulose, polyanhydrides and acrylic polymers.
• an implant with a pore size of at least 0.45 ⁇ m is used.
• the geometry of the implant is selected based upon its intended use at the damage site. For example, an elongated triangular implant may be selected to promote nerve regeneration into the spinal cord dorsal root entry zone while a pentagonal-shaped implant may be used to promote nerve regeneration in the corpus callosum.
• the polymers may serve as synthetic bridges over which nerve regeneration is promoted and scar formation reduced by application of the astrocyte restricted precursor cells at the ends or in the vicinity of the ends of the synthetic bridge.
• an acrylic polymer tube with astrocyte restricted precursor cells of the present invention at one or more ends, or throughout the tube can be used to bridge lesions rostrally or bypass lesions, for example, of the spinal cord, over which nerve regeneration can be induced. Examples of such tubes are set forth in European Patent Publication 286284, and in references by Aebischer et al. (Brain Res. 1988 454:179-187 and Prog. Brain Res. 1988 78:599-603) and Winn et al. (Exp. Neurol. 1989 105:244-250).
• the cells of the present invention can also be used in combination with surgical bypass techniques to promote nerve regeneration and/or to reduce scar formation in a selected region.
• surgical bypass techniques to promote nerve regeneration and/or to reduce scar formation in a selected region. Examples of such techniques which can be routinely adapted to use with the compositions of the present invention are set forth in U.S. Pat. No. 5,202,120, which is herein incorporated by reference in its entirety.
• the astrocyte restricted precursor cells of the present invention are also useful in the identification of genes specific to selected stages of development.
• the cells can serve as a source of mRNA for generation of cDNA libraries that are specific to the stage development of the cells.
• the cells can also be used in the generation of cell lines and cell-specific antibodies for use therapeutically and diagnostically as well.
• Human neural progenitor cells derived from fetal tissue were acquired from Cambrex. Frozen aliquots of cells were thawed and plated on fibronectin/laminin-coated multiwell dishes in Neural Progenitor Cell Basal Medium (NPBM, Cambrex) supplemented with human recombinant basic fibroblast growth factor, human recombinant epidermal growth factor, “neural survival factors”, 5 mg/mL gentamicin, and 5 mg/mL amphotericin-B (Singlequots, Cambrex). Cultures were incubated at 37° C., 5% CO 2 and fixed 24 hours later. These wells were subsequently processed for immunocytochemistry to assess the starting population of Cambrex cells.
• NPBM Neural Progenitor Cell Basal Medium
• hNEPs Human Neuroepithelial Precursor Cells
• ENCAM antibody-coated dishes were prepared by sequentially coating tissue culture dishes with an unlabeled anti-mouse IgM antibody (10 mg/ml) overnight, rinsing dishes with DPBS, followed by coating with 5A5 hybridoma supernatant for 1-3 hours at 37° C. Plates were washed twice with DPBS prior to plating neural progenitor cells.
• NG2 panning dishes were made by coating dishes with an NG2 antibody (1:100) for 1-3 hours at 37° C. The supernatant was then removed (ENCAM ⁇ /NG2 ⁇ cells) and immunostained for A2B5.
• Cells were exposed to antibodies to A2B5 (1:2, Developmental Studies Hybridoma Bank) in NEP media for 1 hour at 37° C., 5% CO 2 .
• a secondary goat anti-mouse IgM-PE labeled antibody was then applied for 1 hour to stain the membranes of live A2B5+ cells.
• oligodendrocyte differentiation cells were plated in a bFGF (10 ng/ml)-containing medium for 2 days and then were switched to a medium containing PDGF (10 ng/ml, Upstate Biotech., Waltham, Mass.) and T3 (50 nM) for 7 days.
• Antibodies to O4, GalC and MBP were used to identify oligodendrocytes in culture.
• Astrocytic differentiation cells were cultured for 5 days in the presence of fetal calf serum (10%, Life Technologies).
• Astrocytes were identified using antibodies to CD44, GFAP and S-100.
• oligodendrocyte differentiation Single cells were grown at a clonal density of 50-200 cells/35 mm dish). Cells were maintained in FGF and CEE for 8-10 days and then CEE was withdrawn to initiate differentiation. For oligodendrocyte differentiation cultures were exposed to PDGF and thyroid hormone. After 5-7 days cultures were labeled with antibodies against GFAP and beta-III tubulin to determine differentiation into astrocytes and neurons, respectively. Generation of oligodendrocytes was assessed 7 to 15 days after the initiation of differentiation. Neuronal and glial differentiation was assessed using antibodies against GFAP, and beta-III tubulin. For oligodendrocyte differentiation, cultures were exposed to PDGF and thyroid hormone and differentiation was assessed using antibodies to O4 and Gal-C.
• Panned/sorted populations of human NEPs were plated on fibronectin/laminin-coated 12 mm coverslips in various conditions to promote differentiation.
• bFGF ng/ml
• NT3 10 ng/ml, Peprotech
• fixed cultures were stained using antibodies to beta-III tubulin to assess the capacity of these cells to differentiate into neurons.
• oligodendrocyte differentiation cells were plated in a bFGF (10 ng/ml)-containing medium for 2 days and then were switched to a medium containing PDGF (10 ng/ml, Upstate Biotech., Waltham, Mass.) and T3 (50 nM) for 7 days.
• Antibodies to O4, GalC and MBP were used to identify oligodendrocytes in culture.
• cells were cultured for 5 days in the presence of fetal calf serum (10%, Life Technologies).
• Astrocytes were identified using antibodies to CD44, GFAP and S-100 ⁇ (Morita et al. Dev. Neurosci. 1997 19:210-218; Gomes et al. Braz. J. Med. Biol. Res. 1999 32:619-631).
• CM primary mouse embryonic fibroblasts
• EEM primary mouse embryonic fibroblasts conditioned medium
• CM was generated from huES cell media (ESM) comprised of 80% Knockout DMEM (Gibco), 20% Knockout Serum replacement (Gibco), 0.1 mM beta-mercaptoethanol, 1 mM glutamine, 1% non-essential amino acids, supplemented with 4 ng/mL hbFGF (Gibco). Cultures were passaged by incubation in 200 units/ml collagenase IV (Gibco) for about 5-10 minutes at 37° C. and then gently dissociated into small clusters in CM.
• Embryoid bodies were formed from undifferentiated ES cultures harvested by incubation with 200 u/mL collagenase at 37° C. for 5-10 minutes. The cells were gently scraped from the dish and resuspended in ultra low attachment polystyrene plates (Corning) in media composed of KO-DMEM, 20% FBS, 1% non-essential amino acids, 1 mM glutamate and 0.1 mM beta-mercaptoethanol. In some experiments, 10 ⁇ M all-trans retinoic acid was added to the EBs in suspension.
• EBs were plated onto poly-l-lysine/FN coated plates in proliferation media comprised of DMEM/F12 with B27 and N2 supplements (Gibco) and 10 ng/mL hEGF, 10 ng/mL hbFGF (Gibco), 1 ng/mL hPDGF-AA (R&D Systems), 1 ng/mL hIGF-1 (R&D Systems).
• proliferation media comprised of DMEM/F12 with B27 and N2 supplements (Gibco) and 10 ng/mL hEGF, 10 ng/mL hbFGF (Gibco), 1 ng/mL hPDGF-AA (R&D Systems), 1 ng/mL hIGF-1 (R&D Systems).
• the cells were harvested with trypsin and replated in differentiation media comprised of Neurobasal media supplemented with B27, 10 ng/mL hNT-3(R&D Systems) and 10 ng/mL h
• Cultures were stained using antibodies against A2B5 (1:2, Developmental Studies Hybridoma Bank), AC133/2 (1:100, Miltenyi Biotec, Auburn, Calif.), beta-III tubulin (1:1000, Sigma), E-NCAM (1:2, SAS, Developmental Studies Hybridoma Bank), GFAP (1:2000, Dako, Carpinteria, Calif.), NG2 (1:100) and O4 (1:2, Developmental Studies Hybridoma Bank). Following fixation, cultures were treated with 0.5% Triton X-100 (Sigma) in PBS for 2 minutes to access intracellular antigens. Fixed coverslips or plates were then treated with primary antibodies in a blocking solution containing Hank's balanced salt solution and 5% calf serum for 1 hour at room temperature.

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Biotechnology (AREA)
• Zoology (AREA)
• Medicinal Chemistry (AREA)
• Wood Science & Technology (AREA)
• Genetics & Genomics (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Cell Biology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Biochemistry (AREA)
• Microbiology (AREA)
• Immunology (AREA)
• General Engineering & Computer Science (AREA)
• Developmental Biology & Embryology (AREA)
• Hematology (AREA)
• Virology (AREA)
• Urology & Nephrology (AREA)
• Molecular Biology (AREA)
• Psychology (AREA)
• Epidemiology (AREA)
• Ophthalmology & Optometry (AREA)
• Analytical Chemistry (AREA)
• Pathology (AREA)
• Tropical Medicine & Parasitology (AREA)
• General Physics & Mathematics (AREA)
• Physics & Mathematics (AREA)

Priority Applications (3)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=27613451

Family Applications (4)

Family Applications After (3)

Country Status (8)

Cited By (2)

Families Citing this family (5)

Citations (5)

Family Cites Families (3)

• 2003
  • 2003-01-23 CA CA2473749A patent/CA2473749C/en not_active Expired - Fee Related
  • 2003-01-23 NZ NZ534381A patent/NZ534381A/en unknown
  • 2003-01-23 KR KR10-2004-7011381A patent/KR20040075957A/ko not_active Application Discontinuation
  • 2003-01-23 EP EP03732101A patent/EP1476020A4/de not_active Withdrawn
  • 2003-01-23 AU AU2003216111A patent/AU2003216111C1/en not_active Ceased
  • 2003-01-23 JP JP2003561348A patent/JP2006503543A/ja active Pending
  • 2003-01-23 US US10/502,224 patent/US20050214940A1/en not_active Abandoned
  • 2003-01-23 WO PCT/US2003/002356 patent/WO2003061392A1/en active Application Filing
• 2008
  • 2008-05-28 JP JP2008139534A patent/JP2008289486A/ja active Pending
• 2009
  • 2009-04-30 US US12/433,060 patent/US8673292B2/en not_active Expired - Lifetime
• 2014
  • 2014-03-10 US US14/202,121 patent/US20140186314A1/en not_active Abandoned
• 2015
  • 2015-01-20 US US14/600,299 patent/US20150152382A1/en not_active Abandoned

Patent Citations (5)

Also Published As

Similar Documents

Legal Events